ARHGAP18

Across TCGA pan-cancer cohorts, ARHGAP18 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGAP18 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARHGAP18 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARHGAP18 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where ARHGAP18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	1.000	0.800	.016	20	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	15	view →
HNSC	DFS	Median	II,III,IV	0.567	0.766	.024	8	view →
LSCC	OS	Quartile	II,III,IV	0.764	1.000	.010	5	view →
GBM	DFS	Tertile	All	0.709	0.858	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARHGAP18–CCRCC (OS)

Open the CCRCC breakdown →